Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Here's why I think this top ASX 100 healthcare share is a buy
Share Market News
Has the ASX 200 reached a top or is this just the beginning of a bull run?
⏸️ ASX Shares
3 excellent ASX healthcare shares to watch in the 2020s
Share Market News
3 ASX shares for the ethical investor
⏸️ ASX Shares
3 stellar blue chip ASX shares to buy right now
⏸️ Investing
Shares or property – which is the better investment?
Healthcare Shares
Why I believe this ASX healthcare share will be a winner through to 2030
⏸️ ASX Shares
I would buy and hold these ASX shares through the 2020s and beyond
How to invest
ASX industries to include in your portfolio for diversification
Healthcare Shares
Why ASX healthcare shares are a no-brainer for the 2020s
⏸️ Investing
Will the ASX healthcare shares outperform again in 2020?
Share Market News
Top brokers name 3 ASX shares to sell next week
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
